New hope for lung cancer patients with brain spread: targeted pill under study

NCT ID NCT06282874

Ongoing Disease control Sponsor: Guangdong Association of Clinical Trials Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests the drug lorlatinib in people with a specific type of lung cancer (ALK-positive) that has spread to the brain or the lining of the brain and spinal cord. The goal is to see how well the drug shrinks these brain tumors. About 41 participants will take lorlatinib once daily, and researchers will track their response and how long they live without the cancer growing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lorlatinib (a targeted cancer pill)
What this could lead to: If it works, this could offer a more effective treatment option for lung cancer that has spread to the brain or spinal cord, potentially improving survival and quality of life.
What could go wrong: This is a small, single-arm study (no comparison group), so results may not be definitive. Side effects of lorlatinib can include liver problems, high cholesterol, and swelling.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer Meningeal Carcinomatosis metastatic malignant neoplasm in the brain neoplastic meningitis non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN METASTASES CARCINOMA, NON-SMALL-CELL LUNG LEPTOMENINGEAL METASTASIS

Contacts and locations

Locations

Guangdong Provincial Perople's Hospital

Guangzhou, Guangdong, 510080, China
Tenth Afﬁliated Hospital, Southern Medical University (Dongguan people's hospital)

Dongguan, Guangdong, 510080, China
The First People's Hospital of Foshan

Foshan, Guangdong, 510080, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.